PharmacoFore, Inc.: Series A $10M

Posted in I - Series A, Q - 4Q11, R - WEST, X - Addiction, X - CNS, X - Neurology, X - Pain, XX - CA

PharmacoFore (San Carlos, CA) a clinical-stage biopharmaceutical company focused on improvement of existing drugs preventing misuse, abuse, and overdose of prescription medications for pain, closed a $10M Series A financing. Participants include Founders Fund.

AuraSense Therapeutics, LLC: Series B $5.4M

Posted in I - Series B, Q - 4Q11, R - MID WEST, X - Cardiology, X - Dermatology, X - Neurology, X - Oncology, XX - IL

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

Nautilus Neurosciences, Inc.: Series A $14.5M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Migraine, X - Neurology, X - Pain, XX - NJ

Nautilus Neurosciences (Bridgewater, NJ) near commercial-stage specialty neurology pharma focused on migraine and acute pain, closed a $14.5M Series A financing. Participants include Tailwind Capital.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!

Neuraltus Pharmaceuticals, Inc.: Series A $17M

Posted in I - Series A, Q - 1Q09, R - WEST, X - ALS, X - Dyskinesia, X - Neurology, XX - CA

Neuraltus Pharmaceuticals (Menlo Park, CA) a preclinical-stage developer of small-molecule drugs focused on Amyotropic Lateral Sclerosis and dyskinesia, closed a $17M Series A financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Satori Pharmaceuticals, Inc.: Series B $22M

Posted in I - Series B, Q - 1Q09, R - NORTH EAST, X - Alzheimer's, X - Neurology, X - Parkinson's, XX - CA

Satori Pharmaceuticals (Cambridge, MA) an early-stage neuroscience company focused on the discovery and development of therapies for Alzheimer’s, Parkinson’s disease and other neurodegenerative disorders closed a $22M Series B financing. Participants include InterWest Partners, Prospect Venture Partners, New Enterprise Associates and PureTech Ventures.

Synosia Therapeutics, Ltd.: Series B $28.7M

Posted in I - Series B, Q - 1Q09, R - INTERNATIONAL, X - Neurology

Synosia Therapeutics (Switzerland) develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology, closed a $28.7M Series B financing. Participants include Aravis Venture, Investor Growth Capital, Swiss Helvetia Fund, Versant Ventures, Abingworth, Novo A/S and 5am Ventures.

Link Medicine Corp.: Series C $40M

Posted in I - Series C, R - NORTH EAST, X - ALS, X - Alzheimer's, X - Neurology

Link Medicine (Cambridge, MA) development-stage company focused on the treatment of several neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis, closed a $40M Series C financing. Participants include Clarus Ventures and SV Life Sciences.

Sierra Neuropharmaceuticals: Series A $21.5M

Posted in I - Series A, Q - 3Q08, R - ROCKY MOUNTAIN, X - Epilepsy, X - Neurology, X - Schizophrenia

Sierra Neuropharmaceuticals (Aurora, CO) development-stage biopharmaceutical company specializing treating neurological disorders, closed a $21.5M Series A financing. Participants include HealthCare Ventures, Morgenthaler Ventures, Sequel Ventures and High Country Venture.

PhysioSonics, Inc.: Series A $4M

Posted in I - Series A, Q - 2Q08, R - NORTH WEST, X - Neurology

PhysioSonics (Seattle, WA) a developer of noninvasive neurologic products, closed a $4M Series A financing. Participants include Johnson & Johnson Development Corp.

MindFrame, Inc.: Series A $6M

Posted in I - Series A, Q - 2Q08, R - WEST, X - Device (Neuromod), X - Ischemia, X - Neurology, X - Stroke

MindFrame (Lake Forrest, CA) developer of devices for ischemic stroke treatment, closed a $6M Series A financing. Participants include SV Life Sciences and Intersect Partners.

Capnia, Inc.: Series C $19.2M

Posted in I - Series C, Q - 2Q08, R - WEST, X - Migraine, X - Neurology

Capnia (Palo Alto, CA) development-stage company focused on therapeutic products using a medical gas delivery system, closed a $19.2M Series C financing. Participants include Asset Management, Vivo Ventures and Teknoinvest.

Knopp Neurosciences, Inc.: Series B $10M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - ALS, X - Neurology

Knopp Neurosciences (Pittsburgh, PA) a drug discovery and development company focused on neurological disorders with a lead compound for amyotrophic lateral sclerosis closed a $10M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

to top of page...